PharmaTelevision - Christelle Dagoneau explains how Px are Helping Pharma and Biotechs from R&D up to clinical stage

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Christelle Dagoneau explains how Px are Helping Pharma and Biotechs from R&D up to clinical stage

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Christelle Dagoneau, PhD, Business Development Director, PX'Therapeutics.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Focus and expertise of PX'Therapeutics

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioPharm America in Boston. On this show I have Christelle Dagoneau, who is Director of Business Development & Marketing at a company called PX'Therapeutics, Grenoble, France. Welcome to the show.

Christelle Dagoneau:

Thank you.

Fintan Walton:

Christelle, tell us about PX'Therapeutics, it's a company that's just about 10-years old, what is the focus of our business?

Christelle Dagoneau:

So we are CRO and CMO company meaning that we are selling R&D and biomanufacturing services to pharma and biotech companies basically we help them to develop their biological product recombinant protein and monoclonal antibody from R&D up to clinical stage.

Fintan Walton:

Right, so you know clearly the whole process of developing protein based therapeutic as you say is complex, because you've got to get the early stages right be able to get a proper protein expressed, so the early stage research that you do is that really focused on trying to optimize the expression systems are you actually involved in the drug discovery process itself?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Christelle Dagoneau

Director

Christelle Dagoneau joined PXT in November 2005 as Business Development Director. Before that, Christelle Dagoneau held various marketing & business development positions mostly in health and life science sectors both in France & in the UK. She holds a PhD in Organic chemistry from the Lyon University and a Master in Technology Management from Grenoble Business School.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

PX'Therapeutics

PX'Therapeutics Funded in 2000 in Grenoble, France, Protein'eXpert has been offering contract research services focusing on the engineering and development of valuable and complex recombinant proteins. Protein'eXpert has then extended its range of services to the biomanufacturing of therapeuticprotein products for early clinical trials via its integrated subsidiary PX'Pharma in 2004. PX'Pharma has been providing dedicated contract services for process development & scale-up optimization, preclinical and clinical cGMP production. In 2007, a new subsidiary named PX'Monoclonals was created to propose services ranging from the generation of high affinity murine monoclonal antibodies to the development of chimeric and humanized antibodies for therapeutic use. On September 2008, Protein'eXpert became PX'Therapeutics. This change of name reflects the company's strategy to accompany biotech and pharma clients all along the development of their biotherapeutic candidates with a mission to optimize timelines and bring value to their pipeline. The combination of protein expertise and manufacturing capabilities of the PX'Therapeutics group allows ensuring a seamless transfer from the discovery stage up to clinical manufacturing steps for complex biotherapeutic projects (therapeuticproteins, recombinant vaccines and monoclonal antibodies). In August 2010, PX'Therapeutics offers new services for absolute quantification of proteins based on PSAQ method through a new subsidiary PROMISE Advanced Proteomics which is a spin-off company from the "Exploring the Dynamics of Proteomes" laboratory (CEA/INSERM/UJF). By the end of Q3-2010, a new cGMP mammalian cell culture facility will also be authorized and opened to our clients and partners.